promising
Ukraine is offering comfortable beds and warm meals to North Korea troops who surrender to them.”You do not need to die senselessly in another country,” Ukraine’s military intelligence agency said.North Korea is believed to have sent thousands of troops to help Russia fight Ukraine. Ukraine is enticing Russia-bound North Korean…
During the Affimed (NASDAQ: NASDAQ:) second quarter 2024 earnings and corporate update call, the company highlighted significant clinical progress with their innate cell engagers, particularly in treating non-small cell lung cancer, Hodgkin lymphoma, and acute myeloid leukemia. The new CEO, Shawn Leland, emphasized the potential of these programs and the…
B.O.S Better Online Solutions (NASDAQ: BOSC), a provider of supply chain and robotics solutions, held an earnings call to discuss its financial performance and operational highlights. CEO Eyal Cohen, alongside Chairman Ziv Dekel and CFO Moshe Zeltzer, presented the company’s progress and future strategies. Despite current market challenges, B.O.S maintains…
Geron (NASDAQ:) Corporation (NASDAQ: GERN), a biopharmaceutical company, has reported encouraging early launch results for its new drug RYTELO, designed to treat lower-risk myelodysplastic syndromes (MDS). As of July 31, 2024, around 160 patients have been treated with RYTELO. The company has successfully penetrated 60% of the top decile 1-4…
In its latest quarterly report, Bata India (NS:) delivered a mixed performance that was slightly better than Goldman Sachs’ expectations but lagged behind its industry peers. The company’s revenue grew by 2.5% year-on-year (YoY) in Q4, surpassing Goldman Sachs (NYSE:)’ estimate of flat growth but falling short of Metro Brands…
MIAMI – Summit Therapeutics Inc. (NASDAQ: NASDAQ:) has announced new data from its Phase II clinical trials of ivonescimab, a novel investigational bispecific antibody, showing significant efficacy in treating patients with advanced non-small cell lung cancer (NSCLC) who have brain metastases. The findings were presented today at the European Lung…
POTOMAC, Md. – IGC Pharma Inc. (NYSE American: IGC) has shared interim results from its Phase 2 clinical trial of IGC-AD1, which is being investigated as a treatment for agitation in patients with Alzheimer’s disease. The data indicates a statistically significant reduction in agitation levels compared to a placebo. The…
